Details of the Drug

General Information of Drug (ID: DMO2TYL)

Drug Name

Ramipril

Synonyms

ramipril; 87333-19-5; Tritace; Altace; Carasel; Triatec; Ramace; Delix; Vesdil; Acovil; Cardace; Lostapres; Quark; Hytren; Ramiprilum [Latin]; Hoe-498; Ramiprilum; Pramace; HOE 498; Altace (TN); UNII-L35JN3I7SJ; CHEMBL1168; L35JN3I7SJ; CHEBI:8774; C23H32N2O5; Ramipril

Indication

Disease Entry	ICD 11	Status	REF
Acute heart failure	BD10-BD13	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[2]

Therapeutic Class

Antiviral Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

416.5

Topological Polar Surface Area (xlogp)

1.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Bioavailability: The bioavailability of drug is 28% [3]
Clearance: The renal clearance of drug is 10.7 mL/min [4]
Elimination: Following oral administration, about 60% of the dose is eliminated in the urine as unchanged ramipril (<2%) and its metabolites [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 27 - 36 hours [3]
Metabolism: The drug is metabolized via the hepatic [3]

Chemical Identifiers

Formula: C23H32N2O5
IUPAC Name: (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
Canonical SMILES: CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O
InChI: InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
InChIKey: HDACQVRGBOVJII-JBDAPHQKSA-N

Cross-matching ID

PubChem CID: 5362129
ChEBI ID: CHEBI:8774
CAS Number: 87333-19-5
DrugBank ID: DB00178
TTD ID: D07FRV
ACDINA ID: D00582

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HUMAN angiotensin-converting enzyme (ACE)	TTGFNPD	ACE_HUMAN	Inhibitor	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 202392.
2	ClinicalTrials.gov (NCT04366050) Ramipril for the Treatment of COVID-19. U.S. National Institutes of Health.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	Meisel S, Shamiss A, Rosenthal T: Clinical pharmacokinetics of ramipril. Clin Pharmacokinet. 1994 Jan;26(1):7-15. doi: 10.2165/00003088-199426010-00002.
5	FDA Approved Products: Altace (ramipril) oral capsules
6	Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020 Apr 14;22(5):31.
7	Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219.